Jan 13 (Reuters) -
The U.S. Food and Drug Administration has extended its
review for the expanded use of Travere Therapeutics'
drug to treat a type of rare kidney disorder, the drugmaker said
on Tuesday.
The agency will now give its decision on April 13,
compared to its previous action date of January 13.